TIGIT and neoplasm: In the clinical trials most anti-TIGIT mAbs used IgG1-Fc, such as Tiragolumab (Roche), Vibostolimab (Merck), and Ociperlimab (BeiGene)34, a common mechanism was the selective depletion of TIGIT-overexpressing Tregs within the tumor microenvironment20.